Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

Y Chen, M Wang, W Zhong, J Zhao - Lung Cancer, 2013 - Elsevier
Introduction Some studies showed that epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor gefitinib could improve the outcome of non-small-cell lung cancer (NSCLC) …
被引用次数：46 相关文章

[引用][C] Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

Y Chen, M Wang, W Zhong, J Zhao - Lung Cancer, 2013 - cir.nii.ac.jp
Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell
lung carcinoma with brain metastasis | CiNii Research CiNii 国立情報学研究所 学術情報 …

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

Y Chen, M Wang, W Zhong… - Lung cancer …, 2013 - pubmed.ncbi.nlm.nih.gov
Introduction Some studies showed that epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor gefitinib could improve the outcome of non-small-cell lung cancer (NSCLC) …

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

Y Chen, M Wang, W Zhong, J Zhao - Lung Cancer, 2013 - hero.epa.gov
INTRODUCTION: Some studies showed that epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor gefitinib could improve the outcome of non-small-cell lung cancer …

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

Y Chen, M Wang, W Zhong, J Zhao - Lung Cancer, 2013 - lungcancerjournal.info
Introduction Some studies showed that epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor gefitinib could improve the outcome of non-small-cell lung cancer (NSCLC) …

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis.

Y Chen, M Wang, W Zhong, J Zhao - Lung Cancer (Amsterdam …, 2013 - europepmc.org
Materials and methods In vitro MDCK-MDR1 assay was used to determine permeability and
efflux ratio (RE) of gefitinib. In vivo pharmacokinetic and pharmacodynamic evaluation was …

[引用][C] Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

YAN CHEN, M WANG, WEI ZHONG, J ZHAO - Lung cancer, 2013 - pascal-francis.inist.fr
Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell
lung carcinoma with brain metastasis CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

Y Chen, M Wang, W Zhong, J Zhao - Lung Cancer, 2013 - infona.pl
Some studies showed that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
gefitinib could improve the outcome of non-small-cell lung cancer (NSCLC) patients with …

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

Y Chen, M Wang, W Zhong, J Zhao - Lung Cancer, 2013 - infona.pl
Some studies showed that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
gefitinib could improve the outcome of non-small-cell lung cancer (NSCLC) patients with …

[引用][C] Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

YAN CHEN, M WANG, WEI ZHONG, J ZHAO - Lung cancer, 2013 - Elsevier